Treatment of ventilator-associated pneumonia and ventilator-associated tracheobronchitis in the intensive care unit

References

1. ↵
   1. Kalanuria AA,
   2. Zai W,
   3. Mirski M

   (2014) Ventilator-associated pneumonia in the ICU. Crit Care 18:208.

   OpenUrlCrossRefPubMed
2. ↵
   1. Torres A,
   2. Ferrer M,
   3. Badia JR

   (2010) Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 51(Suppl 1):S48–S53.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Dallas J,
   2. Skrupky L,
   3. Abebe N,
   4. Boyle WA 3rd.,
   5. Kollef MH

   (2011) Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. Chest 139:513–518.

   OpenUrlCrossRefPubMed
4. ↵
   1. Alp E,
   2. Kiran B,
   3. Altun D,
   4. Kalin G,
   5. Coskun R,
   6. Sungur M,
   7. et al.

   (2011) Changing pattern of antibiotic susceptibility in intensive care units: ten years experience of a university hospital. Anaerobe 17:422–425.

   OpenUrlPubMed
5. 1. Boucher HW,
   2. Talbot GH,
   3. Bradley JS,
   4. Edwards JE,
   5. Gilbert D,
   6. Rice LB,
   7. et al.

   (2009) Bad bugs, no drugs: no ESKAPE!An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. El-Saed A,
   2. Balkhy HH,
   3. Al-Dorzi HM,
   4. Khan R,
   5. Rishu AH,
   6. Arabi YM

   (2013) Acinetobacter is the most common pathogen associated with late-onset and recurrent ventilator-associated pneumonia in an adult intensive care unit in Saudi Arabia. Int J Infect Dis 17:e696–e701.

   OpenUrlCrossRefPubMed
7. ↵
   1. Falagas ME,
   2. Rafailidis PI

   (2007) Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 11:134.

   OpenUrlCrossRefPubMed
8. ↵
   1. Poulikakos P,
   2. Tansarli GS,
   3. Falagas ME

   (2014) Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 33:1675–1685.

   OpenUrlCrossRefPubMed
9. ↵
   1. Decker BK

   (2015) Colistin dosing without pharmacokinetic data: the relic of a bygone era. Crit Care Med 43:1331–132.

   OpenUrl
10. ↵
    1. Li J,
    2. Rayner CR,
    3. Nation RL,
    4. Owen RJ,
    5. Spelman D,
    6. Tan KE,
    7. et al.

    (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:2946–2950.

    OpenUrlAbstract/FREE Full Text
11. ↵
    1. Batirel A,
    2. Balkan II,
    3. Karabay O,
    4. Agalar C,
    5. Akalin S,
    6. Alici O,
    7. et al.

    (2014) Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 33:1311–1322.

    OpenUrlCrossRefPubMed
12. ↵
    1. Kalin G,
    2. Alp E,
    3. Akin A,
    4. Coskun R,
    5. Doganay M

    (2014) Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 42:37–42.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Khawcharoenporn T,
    2. Pruetpongpun N,
    3. Tiamsak P,
    4. Rutchanawech S,
    5. Mundy LM,
    6. Apisarnthanarak A

    (2014) Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents 43:378–382.

    OpenUrlCrossRefPubMed
14. ↵
    1. Pugh R,
    2. Grant C,
    3. Cooke RP,
    4. Dempsey G

    (2015) Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 8:CD007577.

    OpenUrl
15. ↵
    1. Plachouras D,
    2. Karvanen M,
    3. Friberg LE,
    4. Papadomichelakis E,
    5. Antoniadou A,
    6. Tsangaris I,
    7. et al.

    (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:3430–3436.

    OpenUrlAbstract/FREE Full Text
16. ↵
    1. Dalfino L,
    2. Puntillo F,
    3. Mosca A,
    4. Monno R,
    5. Spada ML,
    6. Coppolecchia S,
    7. et al.

    (2012) High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54:1720–1726.

    OpenUrlCrossRefPubMed
17. ↵
    1. Kumar A,
    2. Roberts D,
    3. Wood KE,
    4. Light B,
    5. Parrillo JE,
    6. Sharma S,
    7. et al.

    (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Tamma PD,
    2. Cosgrove SE,
    3. Maragakis LL

    (2012) Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 25:450–470.

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Rello J,
    2. Ulldemolins M,
    3. Lisboa T,
    4. Koulenti D,
    5. Manez R,
    6. Martin-Loeches I,
    7. et al.

    (2011) Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 37:1332–1339.

    OpenUrlAbstract/FREE Full Text
20. ↵
    1. Balkhy HH,
    2. El-Saed A,
    3. Maghraby R,
    4. Al-Dorzi HM,
    5. Khan R,
    6. Rishu AH,
    7. et al.

    (2014) Drug-resistant ventilator associated pneumonia in a tertiary care hospital in Saudi Arabia. Ann Thorac Med 9:104–111.

    OpenUrlCrossRefPubMed
21. ↵
    1. Craven DE,
    2. Lei Y,
    3. Ruthazer R,
    4. Sarwar A,
    5. Hudcova J

    (2013) Incidence and outcomes of ventilator-associated tracheobronchitis and pneumonia. Am J Med 126:542–549.

    OpenUrlCrossRefPubMed
22. ↵
    1. Nseir S,
    2. Favory R,
    3. Jozefowicz E,
    4. Decamps F,
    5. Dewavrin F,
    6. Brunin G,
    7. et al.

    (2008) Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study. Crit Care 12:R62.

    OpenUrlCrossRefPubMed
23. ↵
    1. Palmer LB,
    2. Smaldone GC,
    3. Chen JJ,
    4. Baram D,
    5. Duan T,
    6. Monteforte M,
    7. et al.

    (2008) Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 36:2008–2013.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    1. Korbila IP,
    2. Michalopoulos A,
    3. Rafailidis PI,
    4. Nikita D,
    5. Samonis G,
    6. Falagas ME

    (2010) Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 16:1230–1236.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    1. Tumbarello M,
    2. De Pascale G,
    3. Trecarichi EM,
    4. De Martino S,
    5. Bello G,
    6. Maviglia R,
    7. et al.

    (2013) Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 144:1768–1775.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    1. Rattanaumpawan P,
    2. Lorsutthitham J,
    3. Ungprasert P,
    4. Angkasekwinai N,
    5. Thamlikitkul V

    (2010) Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 65:2645–2649.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    1. Choi HK,
    2. Kim YK,
    3. Kim HY,
    4. Uh Y

    (2014) Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii. Yonsei Med J 55:118–125.

    OpenUrlCrossRefPubMed